Sujal M. Patel Purchases 53,300 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) CEO Sujal M. Patel bought 53,300 shares of Nautilus Biotechnology stock in a transaction that occurred on Wednesday, March 19th. The stock was bought at an average price of $0.99 per share, with a total value of $52,767.00. Following the purchase, the chief executive officer now owns 10,117,788 shares of the company's stock, valued at $10,016,610.12. This trade represents a 0.53 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Nautilus Biotechnology Stock Down 7.9 %

NAUT traded down $0.08 during midday trading on Tuesday, reaching $0.92. 266,881 shares of the company's stock were exchanged, compared to its average volume of 94,425. The firm has a market capitalization of $116.11 million, a price-to-earnings ratio of -1.64 and a beta of 1.25. Nautilus Biotechnology, Inc. has a one year low of $0.93 and a one year high of $3.09. The business has a 50-day simple moving average of $1.52 and a two-hundred day simple moving average of $2.09.

Institutional Investors Weigh In On Nautilus Biotechnology

Several large investors have recently made changes to their positions in NAUT. Virtu Financial LLC acquired a new position in Nautilus Biotechnology in the fourth quarter valued at about $28,000. Cubist Systematic Strategies LLC bought a new position in shares of Nautilus Biotechnology in the fourth quarter valued at approximately $34,000. Squarepoint Ops LLC acquired a new position in shares of Nautilus Biotechnology in the 4th quarter worth approximately $44,000. SG Americas Securities LLC grew its position in Nautilus Biotechnology by 56.3% during the 4th quarter. SG Americas Securities LLC now owns 27,483 shares of the company's stock worth $46,000 after acquiring an additional 9,904 shares during the last quarter. Finally, Palumbo Wealth Management LLC increased its holdings in Nautilus Biotechnology by 45.4% during the 4th quarter. Palumbo Wealth Management LLC now owns 28,475 shares of the company's stock valued at $48,000 after purchasing an additional 8,888 shares in the last quarter. Institutional investors own 50.71% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of brokerages have commented on NAUT. Guggenheim set a $2.50 price objective on Nautilus Biotechnology in a research report on Friday, February 28th. The Goldman Sachs Group lowered Nautilus Biotechnology from a "neutral" rating to a "sell" rating and cut their target price for the company from $2.25 to $1.75 in a research note on Thursday, December 5th.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.